Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
boston blog main
boston top stories
life sciences
national blog main
san francisco blog main
3
×
san francisco top stories
3
×
biotech
boehringer ingelheim
clinical trials
deals
eli lilly
national top stories
new york blog main
new york top stories
rna interference
akcea therapeutics
alexion pharmaceuticals
alnylam pharmaceutials
alnylam pharmaceuticals
arrowhead pharmaceuticals
barry greene
biontech
boston university
curevac
dan ollendorf
dicerna pharmaceuticals
drugs
fda
hepatitis b
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
infectious diseases
inotersen
john berk
john shiver
johnson & johnson
mary o'donnell
moderna therapeutics
What
rna
3
×
ago
companies
deal
medicines
time
abandoning
alnylam
approve
awaits
baggage
bets
bio
biological
cancer
comes
crossed
cut
cuts
date
decades
decision
development
dicerna
discovered
effective
enticed
evidence
fda
fingers
free
friday
gets
hasn’t
historic
interference
latest
long
medicine
messenger
Language
Current search:
rna
×
" san francisco top stories "
×
" san francisco blog main "
×
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines